Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 8/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13833775 | 0.81 | APEX1 (0.67) | APEX1KDM4EMAPTUHRF1TP53 | |
| SCHEMBL13833774 | 0.81 | APEX1 (0.56) | APEX1KDM4ERAB9AMEN1MAPT | |
| SCHEMBL13833708 | 0.81 | APEX1 (0.56) | APEX1KDM4ERAB9AMEN1MAPT | |
| SCHEMBL14788110 | 0.80 | KDM4E (0.56) | APEX1KDM4ERAB9AMEN1MAPT | |
| SCHEMBL13833746 | 0.77 | KDM4E (0.52) | APEX1KDM4ERAB9AMEN1MAPT | |
| Trifluoroacetic Acid SCHEMBL14778261 | 0.76 | UHRF1 (0.64) | APEX1KDM4EMAPTUHRF1TP53 | |
| Trifluoroacetic Acid SCHEMBL14777440 | 0.76 | UHRF1 (0.57) | APEX1KDM4ERAB9AMEN1MAPT | |
| Trifluoroacetic Acid SCHEMBL14777281 | 0.76 | UHRF1 (0.57) | APEX1KDM4ERAB9AMEN1MAPT | |
| SCHEMBL13735036 | 0.76 | APEX1 (1.00) | APEX1KDM4ERAB9AMEN1KMT2A | |
| SCHEMBL2246115 | 0.74 | MAPT (1.00) | KDM4ERAB9AMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2012154888-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | HSPA5, PSMG3, VCP | APEX1 2669/4885KDM4E 3155/4885RAB9A 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.